Biomarker Testing and HER2 Scoring in Endometrial Cancer

Bradley R. Corr, MD, of University of Colorado Cancer Center, and Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, describe how they test patients with endometrial cancer for biomarkers, in conversation with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center. Corr says his institution obtains molecular analysis up front, including POLE, p53, mismatch repair, and HER2, and notes that B7-H4 and TROP2 may become relevant markers. Secord says HER2 is enriched in serous endometrial cancer but that full panel testing may be simpler than testing selected groups, and she is becoming more convinced about POLE testing. The panel discusses the three HER2 scoring systems in use, including the endometrial-specific method, breast cancer scoring, and gastric scoring, and Secord calls HER2 testing complex and subjective. Secord also describes the design of the completed GOG-3026 trial of HER2-directed therapy with carboplatin and paclitaxel.